← 產業報告目錄
Antibody Coupled T-Receptor Therapy Market Size, Share & Trends Analysis Report By Indication (Lymphoma, Breast Cancer, Neuroblastoma, Other Indications), By Region, And By Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-07頁數 180報告編號 INSIGHTACE-bb50962c52
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Industry analysis indicates the Antibody Coupled T-Receptor Therapy Market globally will expand at a 5.89% CAGR during 2023–2031.
At its core, Antibody Coupled T-Receptor Therapy pertains to an immunotherapy modality to have the patient's t cells fight cancer. Stakeholders across the healthcare landscape are growingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold notable shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
Through rigorous analysis of market trends, growth catalysts, restraints, and opportunities, this study offers valuable perspectives for companies, investors, and policymakers navigating this evolving landscape.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Anti-body Coupled T Receptor Therapy Market Snapshot
Chapter 4. Global Anti-body Coupled T Receptor Therapy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Indication Estimates & Trend Analysis
5.1. By Indication, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Indication:
5.2.1. Lymphoma
5.2.2. Breast Cancer
5.2.3. Neuroblastoma
5.2.4. Other Indications
Chapter 6. Anti-body Coupled T Receptor Therapy Market Segmentation 2: Regional Estimates & Trend Analysis
6.1. North America
6.1.1. North America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
6.1.2. North America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
6.2. Europe
6.2.1. Europe Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, 2019-2031
6.2.2. Europe Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.3. Asia Pacific
6.3.1. Asia Pacific Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, 2019-2031
6.3.2. Asia Pacific Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.4. Latin America
6.4.1. Latin America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
6.4.2. Latin America Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
6.5. Middle East & Africa
6.5.1. Middle East & Africa Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
6.5.2. Middle East & Africa Anti-body Coupled T Receptor Therapy Market revenue (US$ Million) by country, 2019-2031
Chapter 7. Competitive Landscape
7.1. Major Mergers and Acquisitions/Strategic Alliances
7.2. Company Profiles
7.2.1. Unum Therapeutics
7.2.2. Pfizer Inc.
7.2.3. Novartis AG
7.2.4. Johnson and Johnson Services, Inc.
7.2.5. GSK plc
7.2.6. The Bristol-Myers Squibb Company
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們